Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM

1 September 2024 (08:51 - 09:09)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Caroline Coats

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Doctor C. Ho (Boston, US)

Presentation thumbnail

Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study

Doctor P. Garcia-Pavia (Majadahonda, ES)

Abstract Slides Video

Presentation thumbnail

Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with an HCM sarcomeric gene mutation

Mr B. Van Driel (Amsterdam, NL)

Abstract Slides Video

Presentation thumbnail

Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis

Doctor A. Masri (Portland, US)

Abstract Slides Video

Access the full session

Session thumbnail

Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

The Event

Event poster

ESC Congress 2024

1 September 2024 08:51 CET

You may be interested in

Congress Presentation

Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial

Congress Presentation

Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM

Congress Presentation

SEQUOIAHCM: Effect of aficamten treatment on patients with hypertrophic obstructive cardiomyopathy by geographical region

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources